2 results
Approved WMOCompleted
To determine the conversion rate of PR to CR (i.e. PET negativity) after a single dose of 90Y-ibritumomab tiuxetan (a dose of 14.8 MBq/kg or 0.4 mCi/kg, max 1184 MBq or 32mCi) in patients with grade 1-3a, stage II, III or IV follicular lymphoma with…
Approved WMOCompleted
The objective of this study is to determine the safety and effectiveness of the Surpass NeuroEndoGraft* System in the endovascular treatment of large or giant wide-necked intracranial aneurysms (IA) in internal carotid artery up to the terminus.